See more : Cauldron Energy Limited (CXU.AX) Income Statement Analysis – Financial Results
Complete financial analysis of The Oncology Institute, Inc. (TOI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of The Oncology Institute, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Chemung Financial Corporation (CHMG) Income Statement Analysis – Financial Results
- Enma Al Rawabi Investment & Real Estate Development Company (9521.SR) Income Statement Analysis – Financial Results
- Berkshire Hills Bancorp, Inc. (BHLB) Income Statement Analysis – Financial Results
- Vantage Towers AG (VTAGY) Income Statement Analysis – Financial Results
- Ironveld Plc (IRON.L) Income Statement Analysis – Financial Results
The Oncology Institute, Inc. (TOI)
About The Oncology Institute, Inc.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 324.24M | 252.48M | 203.00M | 187.51M | 155.41M | 113.16M |
| Cost of Revenue | 264.67M | 200.39M | 162.16M | 150.64M | 125.46M | 86.88M |
| Gross Profit | 59.57M | 52.09M | 40.85M | 36.88M | 29.94M | 26.28M |
| Gross Profit Ratio | 18.37% | 20.63% | 20.12% | 19.67% | 19.27% | 23.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 309.17K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 41.59M | 0.00 | 0.00 |
| SG&A | 113.85M | 119.69M | 83.37M | 41.90M | 29.64M | 20.39M |
| Other Expenses | 22.74M | 4.41M | 3.34M | 3.18M | 2.94M | 1.10M |
| Operating Expenses | 136.59M | 124.10M | 86.71M | 45.07M | 32.59M | 21.49M |
| Cost & Expenses | 401.26M | 324.49M | 248.86M | 195.71M | 158.05M | 108.37M |
| Interest Income | 0.00 | 4.08M | 320.00K | 254.15K | 3.38K | 0.00 |
| Interest Expense | 6.78M | 4.08M | 320.00K | 347.06K | 3.38K | 1.59K |
| Depreciation & Amortization | 5.87M | 4.41M | 3.34M | 3.18M | 2.94M | 1.10M |
| EBITDA | -70.45M | 8.40M | -7.94M | -11.29M | 307.11K | 9.08M |
| EBITDA Ratio | -21.73% | -26.57% | -20.43% | -6.02% | 0.20% | 5.27% |
| Operating Income | -77.02M | -72.01M | -45.86M | -8.20M | -2.63M | 4.79M |
| Operating Income Ratio | -23.75% | -28.52% | -22.59% | -4.37% | -1.70% | 4.23% |
| Total Other Income/Expenses | -6.09M | 81.86M | 34.26M | -6.62M | 6.63K | 71.18K |
| Income Before Tax | -83.10M | 1.90M | -11.60M | -14.81M | -2.64M | 4.86M |
| Income Before Tax Ratio | -25.63% | 0.75% | -5.71% | -7.90% | -1.70% | 4.30% |
| Income Tax Expense | -36.00K | 247.00K | -671.00K | -492.82K | 1.38M | 912.75K |
| Net Income | -83.07M | 1.66M | -10.93M | -14.32M | -4.02M | 3.95M |
| Net Income Ratio | -25.62% | 0.66% | -5.38% | -7.64% | -2.59% | 3.49% |
| EPS | -0.92 | 0.02 | -0.16 | -0.24 | -0.06 | 0.14 |
| EPS Diluted | -0.92 | 0.02 | -0.16 | -0.24 | -0.06 | 0.14 |
| Weighted Avg Shares Out | 73.75M | 72.79M | 66.23M | 59.12M | 64.45M | 28.75M |
| Weighted Avg Shares Out (Dil) | 73.75M | 80.61M | 66.23M | 59.12M | 64.45M | 28.75M |
Grapevine Saves The Oncology Institute Millions On Healthcare Supplies
Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs
The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2024 Earnings Conference Call November 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Operator Good afternoon and welcome to The Oncology...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
The Oncology Institute Announces Third Quarter 2024 Earnings Release Date and Conference Call
CERRITOS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2024 financial results after...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
Constellation Software Inc. and Topicus.com Inc. Announce Results for Topicus.com Inc. for the Third Quarter Ended September 30, 2024
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus” or the “Company”) for the third quarter ended September 30, 2024. Please note...
Source: https://incomestatements.info
Category: Stock Reports